A clinical trial of E0659 nasal gel spray on perennial allergic rhinitis

• Published in: jibi to rinsho Vol. 42; no. 2; pp. 184 - 202
• Main Authors: OKUDA, Minoru, TAKASAKA, Tomonori, INAMURA, Naoki, SATO, Mitsuyoshi, HASHIMOTO, Syo, AWATAGUCHI, Toshiichi, OYAMA, Kenji, SUZUKI, Masaaki, SAKURADA, Takashi, ENDO, Satomi, ISHITOYA, Masako, OSHIMA, Takeshi, NAKANO, Hiroshi, MESHIZUKA, Keisuke, ICHIKAWA, Tomoya, FUKAYA, Takashi, ITO, Yoriko, YOSHIDA, Katsuya, KOBAYASHI, Keiko, WADA, Masashi, YAMAGUCHI, Hiroya, OGAWA, Yutaka, ZUSHO, Hiroyuki, FUJII, Issei, FUKUSATO, Hiroshi, OKAMOTO, Kazuhito, MORISONO, Tetsushi, YAMAKOSHI, Takayuki, KATAGIRI, Jun-ichi, OHASHI, Kazushi
• Format: Journal Article
• Language: Japanese
• Published: JIBI TO RINSHO KAI 20.03.1996
• ISSN: 0447-7227; 2185-1034
• DOI: 10.11334/jibi1954.42.2_184

To determine the optimal regimen for E0659 nasal gel spray in perennial allergic rhinitis, a multicenter single-blind study was carried out by administering E0659 15μgispray in both b.i.d. and t.i.d. regimens, 1. The final global improvement rating was 52% for the b.i.d. group and 43% for the t.i.d. group, based on “good to excellent” responses. Therefore, the result between the b.i.d. and the t.i.d. regimens were considered to be clinically similar. 2. The overall safety rating based on “no safety problems” was 97% for b.i.d. and 98% for the t.i.d. group, so no difference in the overall safety rating was observed between the b.i.d. and the t.i.d. regimens. 3. The utility rating was 57% for the b.i.d. group and 48% for the t.i.d. group based on a finding of “useful to very useful”, so again the findings for the b.i.d. and t.i.d.regimens were found to be similar. Based on the above findings, the b.i.d. treatment regimen is therefore considered to be the optimal regimens for E0659 nasal spray.